GeneWeave Biosciences, a San Jose, CA-based developer of a platform for the rapid detection of infectious disease, has raised $12m in a Series A venture capital funding.
The round was led by Decheng Capital, with participation from existing investors Claremont Creek Ventures and X/Seed Capital.
The company intends to use the funding to complete the development, validation and clearance of the initial test for its platform. Led by CEO Steve Tablak, GeneWeave Biosciences, has developed a molecular diagnostic technology for the detection of life threatening pathogens (GeneScout™).
In conjunction with the funding, Min Cui, managing director at Decheng Capital, will join the company’s board.
FinSMEs
28/02/2012